Blueprint Genetics was founded in 2012, specializes in diagnostics of rare inherited diseases and serves customers in more than 70 countries. Pontos invested in Blueprint Genetics in 2015.

Blueprint Genetics is expected to continue operating independently from its main laboratory in Helsinki, Finland. The acquisition provides a platform for Blueprint Genetics to leverage Quest’s capabilities especially in the United States.